QQQ   294.11 (-0.17%)
AAPL   142.91 (-0.96%)
MSFT   246.85 (-0.39%)
META   148.69 (-0.19%)
GOOGL   98.08 (-0.77%)
AMZN   101.84 (-1.25%)
TSLA   171.63 (-0.92%)
NVDA   200.65 (+2.70%)
NIO   11.72 (-2.90%)
BABA   111.03 (+0.75%)
AMD   81.01 (+7.80%)
T   20.38 (+0.05%)
MU   61.58 (+2.12%)
F   13.65 (+1.04%)
CGC   2.98 (-1.65%)
GE   81.39 (+1.13%)
DIS   108.32 (-0.16%)
AMC   5.42 (+1.31%)
PFE   43.70 (-1.04%)
PYPL   80.77 (-0.88%)
NFLX   358.34 (+1.27%)
QQQ   294.11 (-0.17%)
AAPL   142.91 (-0.96%)
MSFT   246.85 (-0.39%)
META   148.69 (-0.19%)
GOOGL   98.08 (-0.77%)
AMZN   101.84 (-1.25%)
TSLA   171.63 (-0.92%)
NVDA   200.65 (+2.70%)
NIO   11.72 (-2.90%)
BABA   111.03 (+0.75%)
AMD   81.01 (+7.80%)
T   20.38 (+0.05%)
MU   61.58 (+2.12%)
F   13.65 (+1.04%)
CGC   2.98 (-1.65%)
GE   81.39 (+1.13%)
DIS   108.32 (-0.16%)
AMC   5.42 (+1.31%)
PFE   43.70 (-1.04%)
PYPL   80.77 (-0.88%)
NFLX   358.34 (+1.27%)
QQQ   294.11 (-0.17%)
AAPL   142.91 (-0.96%)
MSFT   246.85 (-0.39%)
META   148.69 (-0.19%)
GOOGL   98.08 (-0.77%)
AMZN   101.84 (-1.25%)
TSLA   171.63 (-0.92%)
NVDA   200.65 (+2.70%)
NIO   11.72 (-2.90%)
BABA   111.03 (+0.75%)
AMD   81.01 (+7.80%)
T   20.38 (+0.05%)
MU   61.58 (+2.12%)
F   13.65 (+1.04%)
CGC   2.98 (-1.65%)
GE   81.39 (+1.13%)
DIS   108.32 (-0.16%)
AMC   5.42 (+1.31%)
PFE   43.70 (-1.04%)
PYPL   80.77 (-0.88%)
NFLX   358.34 (+1.27%)
QQQ   294.11 (-0.17%)
AAPL   142.91 (-0.96%)
MSFT   246.85 (-0.39%)
META   148.69 (-0.19%)
GOOGL   98.08 (-0.77%)
AMZN   101.84 (-1.25%)
TSLA   171.63 (-0.92%)
NVDA   200.65 (+2.70%)
NIO   11.72 (-2.90%)
BABA   111.03 (+0.75%)
AMD   81.01 (+7.80%)
T   20.38 (+0.05%)
MU   61.58 (+2.12%)
F   13.65 (+1.04%)
CGC   2.98 (-1.65%)
GE   81.39 (+1.13%)
DIS   108.32 (-0.16%)
AMC   5.42 (+1.31%)
PFE   43.70 (-1.04%)
PYPL   80.77 (-0.88%)
NFLX   358.34 (+1.27%)
LON:HIK

Hikma Pharmaceuticals - HIK Share Forecast, Price & News

GBX 1,700
-8.50 (-0.50%)
(As of 02/1/2023 11:39 AM ET)
Add
Compare
Today's Range
1,686
1,713.50
50-Day Range
1,481
1,720.50
52-Week Range
1,174.50
2,137
Volume
183,452 shs
Average Volume
440,044 shs
Market Capitalization
£3.74 billion
P/E Ratio
1,393.44
Dividend Yield
2.54%
Price Target
GBX 1,712.50

Hikma Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
2.8% Upside
GBX 1,754 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
0.25mentions of Hikma Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
£1.70 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.35 out of 5 stars


HIK stock logo

About Hikma Pharmaceuticals (LON:HIK) Stock

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Receive HIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

HIK Stock News Headlines

Hikma Pharmaceuticals' (HIK) "Buy" Rating Reiterated at Citigroup
Top Lithium Stock To Watch
Today's stock market news features a lithium stock with blue sky potential.
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
FTSE 100 Rallies Led By Energy Stocks
See More Headlines
Receive HIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

HIK Company Calendar

Today
2/01/2023
Next Earnings (Estimated)
2/23/2023

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
8,700
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
GBX 1,754
High Stock Price Forecast
GBX 2,300
Low Stock Price Forecast
GBX 1,350
Forecasted Upside/Downside
+0.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£2.55 billion
Cash Flow
GBX 203.86 per share
Book Value
GBX 988.60 per share

Miscellaneous

Free Float
N/A
Market Cap
£3.74 billion
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Engineer Said Samih Taleb Darwazah (Age 65)
    Exec. Chairman & CEO
    Comp: $2.71M
  • Mr. Mazen Samih Taleb Darwazah (Age 64)
    Exec. Vice Chairman & Pres of MENA
    Comp: $2.11M
  • Mr. Khalid Waleed Hosny Al Nabilsi (Age 50)
    Chief Financial Officer
  • Mr. Hussein Arkhagha
    Company Sec. & Chief Counsel
  • Mr. Bassam Wael Rushdi Kanaan CFA (Age 57)
    CPA, Exec. VP of Corp. Devel. and M&A
  • Ms. Susan Ringdal
    Exec. VP of Strategic Planning & Global Affairs
  • Ms. Majda Labadi
    Exec. VP of Organisational Devel.
  • Mr. Riad Mishlawi
    Pres of Injectables
  • Mr. Brian Hoffmann
    Pres of Generics
  • Mr. Samuel Park
    Global Head of Intellectual Property (IP) & Gen. Counsel for US













HIK Stock - Frequently Asked Questions

Should I buy or sell Hikma Pharmaceuticals stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" HIK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HIK, but not buy additional shares or sell existing shares.
View HIK analyst ratings
or view top-rated stocks.

What is Hikma Pharmaceuticals' stock price forecast for 2023?

5 brokers have issued 1 year price objectives for Hikma Pharmaceuticals' stock. Their HIK share price forecasts range from GBX 1,350 to GBX 2,300. On average, they expect the company's share price to reach GBX 1,754 in the next year. This suggests a possible upside of 2.8% from the stock's current price.
View analysts price targets for HIK
or view top-rated stocks among Wall Street analysts.

How have HIK shares performed in 2023?

Hikma Pharmaceuticals' stock was trading at GBX 1,552 at the beginning of the year. Since then, HIK shares have increased by 10.0% and is now trading at GBX 1,707.
View the best growth stocks for 2023 here
.

When is Hikma Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our HIK earnings forecast
.

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals announced a dividend on Thursday, August 4th. Investors of record on Thursday, August 18th will be given a dividend of GBX 0.19 per share on Monday, September 19th. This represents a yield of 0.89%. The ex-dividend date is Thursday, August 18th. The official announcement can be viewed at this link.
Read our dividend analysis for HIK
.

Is Hikma Pharmaceuticals a good dividend stock?

Hikma Pharmaceuticals (LON:HIK) pays an annual dividend of GBX 0.52 per share and currently has a dividend yield of 2.54%. The dividend payout ratio is 42.65%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for HIK.

What other stocks do shareholders of Hikma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Gran Tierra Energy (GTE), Och-Ziff Capital Management Group (OZM) and Belden (BDC).

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

How do I buy shares of Hikma Pharmaceuticals?

Shares of HIK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Hikma Pharmaceuticals' stock price today?

One share of HIK stock can currently be purchased for approximately GBX 1,707.

How much money does Hikma Pharmaceuticals make?

Hikma Pharmaceuticals (LON:HIK) has a market capitalization of £3.76 billion and generates £2.55 billion in revenue each year.

How many employees does Hikma Pharmaceuticals have?

The company employs 8,700 workers across the globe.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The official website for the company is www.hikma.com. The company can be reached via phone at +44-20-73992760.

This page (LON:HIK) was last updated on 2/1/2023 by MarketBeat.com Staff